Presence of Serum Antinuclear Antibodies Does Not Impact Outcomes in HBV-Related Acute-on-Chronic Liver Failure

Table 2

Risk factors for 90-day mortality in patients with ACLF.

Baseline variables	Univariate			Multivariate
	Odds ratio	95% CI		Odds ratio	95% CI
Age (years)	0.988	0.949–1.029	0.57
Male	1.211	0.242–6.053	0.82
LC	1.312	0.338–5.094	0.70
HE	0.537	0.189–1.522	0.24
SBP	0.592	0.150–2.339	0.45
ANA (+)	0.938	0.207–4.259	0.93
ALT	1.000	0.997–1.002	0.66
AST	1.001	0.999–1.004	0.36
TBil	1.004	0.999–1.009	0.09	1.005	1.000–1.009	0.04
INR	2.126	0.889–5.084	0.09	2.559	1.215–5.387	0.01
Creatinine	1.017	0.999–1.035	0.06
Serum sodium	0.891	0.780–1.016	0.09
PLT	0.982	0.966–1.000	0.04	0.983	0.971–0.996	<0.01
WBC	1.216	0.978–1.510	0.08	1.307	1.103–1.550	<0.01

ACLF, acute-on-chronic liver failure; 95% CI, 95% confidence interval; LC, liver cirrhosis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ANA, antinuclear antibodies; CHE, cholinesterase; TBil, total bilirubin; INR, international normalized ratio; PLT, platelet; WBC, white blood cell.